Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
An update on potentially effective antibacterial drugs in the late-stage development pipeline is provided, in the hope of encouraging collaboration between industry, academia, the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention work productively together.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
- H. Boucher, M. Wilcox, G. Talbot, S. Puttagunta, Anita F. Das, M. Dunne
- MedicineNew England Journal of Medicine
- 4 June 2014
Once-weekly intravenous dalbavancin was not inferior to twice-daily intravenous vancomycin followed by oral linezolid for the treatment of acute bacterial skin and skin-structure infection.
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
If the antimicrobial resistance crisis is to be addressed, a concerted, grassroots effort led by the medical community will be required and could mean a literal return to the preantibiotic era for many types of infections.
Epidemiology of methicillin-resistant Staphylococcus aureus.
The trends in both nosocomial and community-associated MRSA infections are examined and recent studies of the mechanisms that allow S. aureus to become resistant to currently available drugs are explored.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial…
- J. Motsch, Cláudia Murta de Oliveira, Amanda Paschke
- Medicine, BiologyClinical Infectious Diseases
- 10 August 2019
Imipenem/relebactam is an efficacious and well-tolerated treatment option for carbapenem-nonsusceptible infections and should be considered as a first-line treatment for hospital-acquired/ventilator-associated pneumonia.
Combating antimicrobial resistance: policy recommendations to save lives.
This policy paper summarizes the Infectious Diseases Society of America’s (IDSA) recommendations about how best to address the synergistic crises of rising rates of antibiotic resistance and waning approvals of new antibiotics.
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
Voriconazole is becoming a new standard of therapy for invasive aspergillosis and has several important safety issues, including visual adverse events, hepatic enzyme elevation and skin reactions, as well as a number of drug interactions.
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
The V710 vaccine was not significantly more efficacious than placebo in preventing either the primary end points or secondary end points despite eliciting robust antibody responses at the end of the study.
Serious infections caused by methicillin-resistant Staphylococcus aureus.
The clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis are described and a brief review of community-associated MRSA infections and preventive strategies directed against MRSA is presented.